Brokerages predict that Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) will announce $0.39 earnings per share for the current quarter, according to Zacks. Six analysts have issued estimates for Arrowhead Pharmaceuticals’ earnings, with estimates ranging from ($0.67) to $2.04. Arrowhead Pharmaceuticals reported earnings of ($0.26) per share during the same quarter last year, which would indicate a positive year over year growth rate of 250%. The company is expected to issue its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that Arrowhead Pharmaceuticals will report full year earnings of ($0.98) per share for the current fiscal year, with EPS estimates ranging from ($2.75) to $2.36. For the next year, analysts expect that the firm will post earnings of ($1.54) per share, with EPS estimates ranging from ($3.92) to $1.81. Zacks’ EPS calculations are an average based on a survey of analysts that cover Arrowhead Pharmaceuticals.
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Rating) last issued its quarterly earnings results on Wednesday, February 2nd. The biotechnology company reported ($0.60) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.38). The company had revenue of $27.44 million during the quarter, compared to the consensus estimate of $67.30 million. Arrowhead Pharmaceuticals had a negative return on equity of 43.99% and a negative net margin of 126.70%. During the same period in the previous year, the company earned ($0.20) EPS.
Shares of ARWR stock traded up $0.98 on Thursday, hitting $45.31. 3,333 shares of the company’s stock traded hands, compared to its average volume of 722,414. Arrowhead Pharmaceuticals has a one year low of $38.89 and a one year high of $93.66. The company’s fifty day simple moving average is $46.00 and its 200 day simple moving average is $58.27. The stock has a market capitalization of $4.78 billion, a price-to-earnings ratio of -25.70 and a beta of 1.37.
In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 146,388 shares of the firm’s stock in a transaction dated Friday, February 11th. The shares were sold at an average price of $51.91, for a total transaction of $7,599,001.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 3.20% of the stock is owned by company insiders.
Large investors have recently added to or reduced their stakes in the business. Sageworth Trust Co of South Dakota bought a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter worth approximately $25,000. Parallel Advisors LLC boosted its holdings in shares of Arrowhead Pharmaceuticals by 142.3% in the fourth quarter. Parallel Advisors LLC now owns 819 shares of the biotechnology company’s stock worth $54,000 after buying an additional 481 shares during the last quarter. First Horizon Advisors Inc. boosted its holdings in shares of Arrowhead Pharmaceuticals by 760.4% in the fourth quarter. First Horizon Advisors Inc. now owns 912 shares of the biotechnology company’s stock worth $60,000 after buying an additional 806 shares during the last quarter. Lindbrook Capital LLC boosted its holdings in shares of Arrowhead Pharmaceuticals by 10,300.0% in the fourth quarter. Lindbrook Capital LLC now owns 1,144 shares of the biotechnology company’s stock worth $76,000 after buying an additional 1,133 shares during the last quarter. Finally, Assetmark Inc. purchased a new position in shares of Arrowhead Pharmaceuticals in the third quarter worth approximately $84,000. Institutional investors and hedge funds own 63.20% of the company’s stock.
Arrowhead Pharmaceuticals Company Profile (Get Rating)
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma.
- Get a free copy of the StockNews.com research report on Arrowhead Pharmaceuticals (ARWR)
- Workhorse Johnson & Johnson Plows New All-Time Highs
- Fastenal Stock is Ready to Sprint Higher
- J.B. Hunt Transportation Services Fires On All Cylinders
- 3 No-Brainer Stocks to Buy with $1000
- Rite Aid Stock is Getting Cheap Enough to Buy Here
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.